Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on August 09, 2017, 10:12:24 am
-
The Food and Drug Administration (FDA) has approved AbbVie’s once-daily Mavyret to treat all six major genotypes of hepatitis C virus (HCV).The pangenotypic tablet includes the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir.
The approval is for an eight-week regimen for those new to treatment who do not have cirrhosis or who have compensated cirrhosis (the milder form of the advanced liver disease), including those with moderate to severe chronic kidney disease and those who are on dialysis.
Read more...
https://www.hepmag.com/article/fda-oks-abbvies-mavyret-hepatitis-c-genotypes